Departments of Medicine, Baylor University Medical Center, Dallas, TX, USA.
Liver Transpl. 2010 Apr;16(4):431-9. doi: 10.1002/lt.22004.
Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty-seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18). Fatty liver developed in 31% and was more common when the pretransplant diagnosis was NASH (45% at 5 years versus 23% for cryptogenic cirrhosis, P = 0.007). NASH developed in only 4% and occurred exclusively when steatosis had already occurred. Steatosis after liver transplantation was associated with the baseline body weight and body mass index by univariate analyses, but no pretransplant or posttransplant characteristic independently predicted steatosis after liver transplantation because obesity was so common in all groups. Five percent and 10% developed bridging fibrosis or cirrhosis after 5 and 10 years, respectively, and this was more common after NASH (31%) than in those who developed steatosis alone (6%) or had no fat (3%, P = 0.002). One-, 5-, and 10-year survival was the same in patients who underwent transplantation for cryptogenic cirrhosis or NASH (86%, 71%, and 56%) and in patients who underwent transplantation for other indications (86%, 71%, and 53%; not significant), but death was more often due to cardiovascular disease and less likely from recurrent liver disease. In conclusion, fatty liver is common after liver transplantation for cryptogenic cirrhosis or NASH but is twice as common in the latter group; this suggests that some cryptogenic cirrhosis, but perhaps not all, is caused by NASH. Posttransplant NASH is unusual, and steatosis appears to be a prerequisite. Advanced fibrosis is uncommon, and survival is the same as that of patients who undergo transplantation for other causes.
非酒精性脂肪性肝炎(NASH)可能是许多隐源性肝硬化的原因。如果是这样,那么脂肪变性可能在肝移植后复发。1986 年至 2004 年间,2052 例患者因慢性肝病接受了初次肝移植。对肝活检样本进行了脂肪变性和纤维化评估。257 例(12%)患者在移植前被诊断为隐源性肝硬化(239 例)或 NASH(18 例)。脂肪性肝病的发生率为 31%,而在 NASH 患者中更为常见(5 年时为 45%,而隐源性肝硬化为 23%,P=0.007)。NASH 的发生率仅为 4%,且仅在已经发生脂肪变性时才发生。单变量分析显示,肝移植后脂肪变性与基线体重和体重指数相关,但没有任何移植前或移植后特征可独立预测肝移植后的脂肪变性,因为所有组中肥胖都很常见。分别有 5%和 10%的患者在 5 年和 10 年后发生桥接纤维化或肝硬化,在 NASH 患者中更为常见(31%),而在单独发生脂肪变性的患者(6%)或无脂肪的患者(3%,P=0.002)中则不常见。对于因隐源性肝硬化或 NASH 而接受移植的患者,1 年、5 年和 10 年的生存率相同(分别为 86%、71%和 56%),而对于因其他原因而接受移植的患者也是如此(分别为 86%、71%和 53%;无显著性差异),但是死亡更常见于心血管疾病,而不是复发性肝病。总之,隐源性肝硬化或 NASH 患者肝移植后发生脂肪肝很常见,但在后一组中更为常见,这表明一些隐源性肝硬化,但可能并非全部,是由 NASH 引起的。肝移植后发生 NASH 不常见,且脂肪变性似乎是一个前提。晚期纤维化并不常见,生存率与因其他原因接受移植的患者相同。